ArticleInternational urology and nephrology2026
Profile of FGF23 and NTproBNP levels and their association with left ventricular hypertrophy in children and adolescents with CKD.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWhile N-terminal pro-B-type natriuretic peptide (NTproBNP) and fibroblast growth factor 23 (FGF23) have independently been evaluated for identification of left ventricular hypertrophy (LVH) in adults, their utility in children is underexplored.
methodsThis cross-sectional study was conducted in children and adolescents (5-18 years) with CKD; those with severe anemia, congestive heart failure or congenital heart disease were excluded. Clinical assessment, hemogram, kidney function tests, and bone mineral metabolism parameters were recorded. Serum FGF23 was measured by ELISA and NTproBNP by chemiluminescence-based kits. Echocardiography was done in children (CKD stages 3-5) within 2 weeks of blood investigations.
resultsOf 60 patients with median (IQR) age 10 (7;12) years enrolled, hypertension was present in 28 (46.6%). NTproBNP was elevated in 40% and FGF23 in 60%. LVH was found in 12 (33.3%) out of the total 36 subjects in CKD stage 3-5. NTproBNP had a significant correlation with hypertension (p < 0.01). The sensitivity and specificity of NTproBNP, eGFR-adjusted NTproBNP and FGF23 to predict LVH were 91.7% and 65.2% (AUC 0.69), 91.7% and 52.2% (AUC 0.53), and 41.7% and 82.6% (AUC 0.51), respectively. Combined FGF23 and NTproBNP achieved sensitivity of 55% and specificity of 100% which was unchanged after eGFR adjustment.
conclusionsNTproBNP showed a high sensitivity for predicting LVH, and the specificity nearly reached 100% when combining NTproBNP with FGF23, indicating its potential as a screening tool where availability of echocardiography is limited.
Indexed as
Identifiers
42611123What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.